Details of the Drug Combinations

General Information of This Drug (ID: DM471KJ)

Drug Name
Omeprazole   DM471KJ
Synonyms Losec (TN)
Indication
Disease Entry ICD 11 Status REF
Cystic fibrosis CA25 Approved [1]
Gastric ulcer DA60 Approved [1]
Gastrinoma 2C10.1 Approved [1]
Gastroesophageal reflux disease DA22.Z Approved [2]
Laryngeal disorder N.A. Approved [1]
Nausea MD90 Approved [1]
Peptic esophagitis N.A. Approved [1]
Peptic ulcer DA61 Approved [1]
Congenital laryngomalacia N.A. Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Antiulcer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Omeprazole + Mitomycin DC1UADJ Mitomycin Diffuse large B cell lymphoma (Cell Line: TMD8) [3]
Omeprazole + Idarubicin DCQ8LGC Idarubicin Glioblastoma? (Cell Line: T98G) [3]
Omeprazole + Ibrutinib DCGAYZN Ibrutinib Diffuse large B cell lymphoma (Cell Line: TMD8) [3]
------------------------------------------------------------------------------------
28 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
MK-1775 + Omeprazole DCCT636 MK-1775 Advanced Solid Tumours [4]
Omeprazole + Regorafenib DCHWZY8 Regorafenib Neoplasms [5]
Omeprazole + Clarithromycin DC0MNTM Clarithromycin Helicobacter Pylori Infection [6]
Omeprazole + Esomeprazole DC4ANWN Esomeprazole Reflux Esophagitis [7]
Omeprazole + Etoricoxib DC5GOAS Etoricoxib Knee, Osteoarthritis (OA) [8]
Omeprazole + Vandetanib DC5L4RV Vandetanib Medullary Thyroid Cancer [9]
Omeprazole + Pantoprazole DCN28LH Pantoprazole Acute Coronary Syndromes [10]
Omeprazole + Boceprevir DCQOHU2 Boceprevir HCV Infections [11]
Omeprazole + Raltegravir DCYDJKZ Raltegravir HIV-1 Infection [12]
Omeprazole + Lansoprazole DCGZBCQ Lansoprazole Ulcer [13]
Omeprazole + Cyclophosphamide DCRV9OK Cyclophosphamide Breast Neoplasm [14]
Omeprazole + Risdiplam DC37YLX Risdiplam Muscular Atrophy, Spinal [15]
Omeprazole + Telotristat ethyl DC8ZUTA Telotristat ethyl Drug-drug Interaction [16]
Omeprazole + Samatasvir DCA8OD0 Samatasvir Chronic Hepatitis C Infection [17]
Omeprazole + GSK1325756 DCF4525 GSK1325756 Pulmonary Disease, Chronic Obstructive [18]
Omeprazole + Tapentadol hydrochloride DCFR9U4 Tapentadol hydrochloride Pharmacokinetic [19]
Omeprazole + Semaglutide DCZCFTW Semaglutide Diabetes [20]
Ranitidine + Omeprazole DCOLNCA Ranitidine Cough [21]
Omeprazole + Cyclophosphamide DCXJHN7 Cyclophosphamide Squamous Cell Carcinoma of the Oral Cavity [22]
Dexamethasone + Omeprazole DCNVEMZ Dexamethasone Neurocysticercosis [23]
Omeprazole + Febuxostat DCEGNCJ Febuxostat Gout [24]
Omeprazole + Allopurinol DCYSVR0 Allopurinol Gout [24]
Omeprazole + Linaclotide DCBSVZL Linaclotide Functional Dyspepsia [25]
Omeprazole + Itopride DCN9TTW Itopride Functional Dyspepsia [25]
Omeprazole + Amoxicillin DC1DU43 Amoxicillin Helicobacter Pylori Infection [26]
Omeprazole + Fluticasone DC4Y7AH Fluticasone Eosinophilic Esophagitis [27]
Omeprazole + Pantoprazole DCIUVQM Pantoprazole Coronary Artery Disease [28]
Ranitidine + Omeprazole DC5KN8C Ranitidine Eustachian Tube Dysfunction [29]
------------------------------------------------------------------------------------
⏷ Show the Full List of 28 DrugCom(s)

References

1 Omeprazole FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4279).
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 ClinicalTrials.gov (NCT04959266) A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib
5 ClinicalTrials.gov (NCT01287598) BAY73-4506 Probe Substrate Study
6 ClinicalTrials.gov (NCT01593592) Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients
7 ClinicalTrials.gov (NCT00634114) Reflux Esophagitis Phase III Study (Maintenance Treatment)
8 ClinicalTrials.gov (NCT05256342) Biomarkers for Prediction of Analgesic Efficacy in Knee OA.
9 ClinicalTrials.gov (NCT01539655) Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib
10 ClinicalTrials.gov (NCT01735227) Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN)
11 ClinicalTrials.gov (NCT01470690) Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO)
12 ClinicalTrials.gov (NCT01000818) A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)
13 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
14 ClinicalTrials.gov (NCT02950259) Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
15 ClinicalTrials.gov (NCT04718181) Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants
16 ClinicalTrials.gov (NCT03302845) A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
17 ClinicalTrials.gov (NCT01813552) To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006). U.S. National Institutes of Health.
18 ClinicalTrials.gov (NCT03457727) GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects
19 ClinicalTrials.gov (NCT03979989) Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol)
20 ClinicalTrials.gov (NCT02249871) Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects
21 ClinicalTrials.gov (NCT00668317) Bronchial Hyper-responsiveness in Reflux Cough
22 ClinicalTrials.gov (NCT02609386) IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
23 ClinicalTrials.gov (NCT00290823) Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients
24 ClinicalTrials.gov (NCT02500641) Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout
25 ClinicalTrials.gov (NCT05134584) Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders
26 ClinicalTrials.gov (NCT05342532) High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population
27 ClinicalTrials.gov (NCT03781596) EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone
28 ClinicalTrials.gov (NCT02028234) "Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER-
29 ClinicalTrials.gov (NCT02123498) The Study of Eustachian Tube Dysfunction and Laryngopharyngeal Reflux